Mark Farrah develops new database tool for comparative analysis of Medicare Advantage and PDP benefit packages

In a recent customer update, Mark Farrah Associates confirmed that Medicare Advantage membership continues to climb, prior to the 2010 open enrollment season. Medicare Advantage enrollment reached 11,211,066 members as of September 2009, an increase of 38,526 members over August 2009. Prescription Drug Plans increased enrollment by 23,426 members; total PDP enrollment was 17,530,462 as of September 2009. Mark Farrah Associates also released the Tennessee Medicare Market Overview, the latest in a series of state analysis briefs. Tennessee is a largely rural state, where more than half of the individuals eligible for Medicare live outside the four largest population centers. The state’s 23% Medicare Advantage penetration is higher than the average rate of 21% for the rest of the United States. Tennessee’s Medicare Advantage market is very competitive with the top three plans: Humana, HealthSpring and UnitedHealth commanding 30%, 24% and 20% market share, respectively. Other Medicare Advantage Market Overviews available through Medicare Business Online™ include AZ, CA, FL, GA, IL, KY, MI, MN, NY, OH, OR, PA, TN, TX and WA.

Mark Farrah Associates’ new Medicare Benefits Analyzer product, developed in partnership with Strenuus, is a customer requested database tool for comprehensive, comparative analysis of Medicare plan benefits by geographic market. Now, in addition to detailed membership data, subscribers may review more than 60 plan design attributes for all Medicare Advantage plans nationwide. The product also includes benefit details for all stand-alone PDPs. With a user-friendly interface, the web database affords easy querying and comparative analysis of Medicare Advantage and PDP benefit packages. Subscriptions are offered for single state or 50-state access.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New vial size could save Medicare millions on Alzheimer's drug